Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center,...
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical...
MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial...
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market...
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ,...
NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings
The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts...
Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma
Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd...
LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product
Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with...
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...
Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages
The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price...
Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor,...
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...
Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai...
Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its...
Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions...
Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch
US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical...
Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China
Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment...
Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software
Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...